Hiroaki Yamazaki

A 3-styrylchromone converted from trimebutine 3D pharmacophore possesses dual suppressive effects on RAGE and TLR4 signaling pathways.

F. Uchiumi, H. Sakagami, S. Tanuma, 2021, Biochemical and biophysical research communications.

Structural Basis of Beneficial Design for Effective Nicotinamide Phosphoribosyltransferase Inhibitors

N. Tanuma, F. Uchiumi, S. Tanuma, 2020, Molecules.

A Novel PEGylation Method for Improving the Pharmacokinetic Properties of Anti-Interleukin-17A RNA Aptamers

Masakazu Nagamine, Hiroaki Yamazaki, K. Haruta, 2017, Nucleic acid therapeutics.

A Dual Anti-Inflammatory and Anti-Proliferative 3-Styrylchromone Derivative Synergistically Enhances the Anti-Cancer Effects of DNA-Damaging Agents on Colon Cancer Cells by Targeting HMGB1-RAGE-ERK1/2 Signaling

S. Amano, H. Sakagami, S. Tanuma, 2022, International journal of molecular sciences.

A Unique Anti-Cancer 3-Styrylchromone Suppresses Inflammatory Response via HMGB1-RAGE Signaling

H. Sakagami, S. Tanuma, A. Yoshimori, 2021, Medicines.

Trimebutine suppresses Toll-like receptor 2/4/7/8/9 signaling pathways in macrophages.

F. Uchiumi, T. Yokomizo, S. Tanuma, 2021, Archives of biochemistry and biophysics.